| Overview |
| bs-2016R-Cy7 |
| Integrin Alpha V + Beta1 Antibody, Cy7 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy7 |
| Rabbit |
| Mixed KLH conjugated syntheticpeptides for human Integrin Alpha V and human Integrin Beta1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3685, 3688 |
| Cytoplasm, Secreted |
| Integrin alpha-V: Integrin alpha-V, Vitronectin receptor subunit alpha, CD51
Integrin beta-1: Fibronectin receptor subunit beta, Glycoprotein IIa, GPIIA, VLA-4 subunit beta, CD29 |
| The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz